D4 Thermal Shock
En vente sur le marché américain (selon le DSLD)
Cellucor, food supplement from the US market
D4 Thermal Shock (Cellucor), a food supplement au code-barres 810390025220, is described by its US market label. If sold in France, it would be subject to 1 point of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
If this product were sold in France
- Conditions légales
Salix alba L.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux personnes souffrant d'allergie aux dérivés salicylés.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Cellucor
- Barcode
- 810390025220
- Form
- Capsule
- One serving
- 1 capsule
- Servings
- up to 2 servings per day
- Other ingredients (in English, as written)
- Capsule Shell, Microcrystalline Cellulose, Stearic Acid, Magnesium Stearate, Silicon Dioxide
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Proprietary Blend | Blend | 588 mg |
| Amla fruit extract (Phyllanthus emblica) | Plant | not stated |
| Caffeine Anhydrous | Other substance | 150 mg |
| White Willow bark extract (Salix alba) | Plant | not stated |
| Octopamine HCl | Other substance | not stated |
| Yohimbe (Pausinystalia yohimbe) bark extract (Pausinystalia johimbe) | Plant | not stated |
| Evodia rutaecarpa fruit extract | Plant | not stated |
| Clary Sage whole herb extract (Salvia sclarea) | Plant | not stated |
| Passion Flower (Passiflora incarnata) | Plant | not stated |
| N-Acetyl-L-Tyrosine | Other substance | not stated |
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: D4 Thermal Shock
Entered into DSLD on 23 May 2014. En vente sur le marché américain (selon le DSLD).- Active ingredient added : Evodiamine Sclareolide (quantity not stated)
- Active ingredient added : Passion Flower extract (quantity not stated)
- Active ingredient added : Yohimbe bark extract (quantity not stated)
- Active ingredient removed : Clary Sage whole herb extract (quantity not stated)
- Active ingredient removed : Evodia rutaecarpa fruit extract (quantity not stated)
- Active ingredient removed : Passion Flower (quantity not stated)
- Active ingredient removed : Yohimbe (Pausinystalia yohimbe) bark extract (quantity not stated)
- Same quantity, different name: Caffeine in this version; Caffeine Anhydrous on the displayed label (150 mg)
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Amla fruit extract
Read the warning, when it applies and the studies cited
Amla - Phyllanthus Emblica
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (HC 2009).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Applies to products providing more than 3 grams of amla, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (HC 2009).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Amlapitta, Digestive tonic.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Laxative.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (HC 2009; Pray 2006; CPhA 2002).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Condition of application: Laxative.
Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Condition of application: Amlapitta, Antioxidant, Digestive tonic, Rasayana or Eye tonic.
When using this product you may experience a laxative effect.
- White Willow bark extract
Read the warning, when it applies and the studies cited
WILLOW BARK
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have asthma or peptic ulcer disease (EMA 2017).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or products containing salicylates (e.g., acetylsalicylic acid or non-steroidal anti-inflammatory drugs) (EMA 2017).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you are pregnant or breastfeeding (EMA 2017; Brinker 2010; Wichtl 2004; ESCOP 2003; Barnes et al. 2002; Blumenthal et al. 2000).
6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Do not use if you are allergic to salicylates (EMA 2017; Brinker 2010; Wichtl 2004, ESCOP 2003; Barnes et al. 2002; Blumenthal et al. 2000).
6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
When using this product you may experience gastrointestinal discomfort/disturbances (EMA 2017; Brinker 2010; Wichtl 2004; ESCOP 2003; Barnes et al. 2002; Blumenthal et al. 2000)
6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- Passion Flower
Read the warning, when it applies and the studies cited
PASSIONFLOWER -PASSIFLORA INCARNATA
Route of administration: Oral
Cautions and warnings
Condition of application: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Berardi et al. 2002: DiPiro et al. 2002).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid taking with alcohol or products that cause drowsiness (EMA 2014; Brinker 2010).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2014).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Cellucor
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.